Table 3.
Clinical studies using other types of stem cells, HUCBs and TNCs.
| Reference | Patients, n Stem cell type |
Mean follow-up, months | Continent (no pads), and improvement (1–2 pads), n/N (%) |
Injection site Periurethral injection rhabdosphincter or submucosa (o’clock positions) |
Clinical evaluation | Functional outcomes |
|---|---|---|---|---|---|---|
| Lee et al., 2010 [30] | 39 Females only 36 completed follow-up Heterologous HUCBs | 1, 3,12 | 13/36 (36) continent 13/36 (36) improvement 10/36 (27) persistent SUI |
4,8 | MUCP | MUCP/PVR 1-h pad test/cough test/ICIQ-UI/ICIQ-QOL |
| Shirvan et al., 2013 [31] | 9 Females TNCs/platelets | 1, 3, 6 | 8/9 improvement 1/9 persistent SUI |
1.5, 3, 4.5, 6, 7.5, 9, 12 | MUCP ↑ (~25 cmH2O) | ↑ MUCP (from <30 cmH2O) |
ICIQ-(QOL)(UI): International Consultation on Incontinence Questionnaire (Quality of life) (Urinary Incontinence); MUCP: maximum urethral closure pressure; PVR: post-void residual urine volume.